BIOMAT Database Logo BIOMAT Database Logo

Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia. 2000

J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

There are few reports about the occurrence of hepatic VOD after BMT for severe aplastic anemia (SAA). We prospectively studied 17 patients with SAA after allogeneic BMT for the occurrence and severity of VOD. Plasma levels of protein C, protein S, antithrombin III, vWF, t-PA and PAI-1 were determined before preparative chemotherapy, on the day of marrow infusion, and on days 7, 14 and 21. VOD occurred in seven patients (41.2%) at a median of day 1 (range, day -2 to 15). Five had mild, and two moderate VOD. Platelet transfusion requirements were higher in the patients with VOD. The plasma levels of natural anticoagulants such as protein C, free protein S and antithrombin III decreased significantly on day 0 from the baseline levels. Plasma levels of t-PA, PAI-1 and vWF increased significantly in the early post-transplant period compared to the baseline levels. The mean plasma levels of t-PA on day 7 (P = 0.016) and PAI-1 on days 0 and 7 (P = 0.016, 0.032) were higher in the patients with VOD. In summary, we observed hypercoagulability and a high incidence of VOD after allogeneic BMT for SAA. Levels of t-PA and PAI-1 were significantly higher in the patients with VOD after BMT.

UI MeSH Term Description Entries
D008297 Male Males
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006487 Hemostasis The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION. Hemostases
D006504 Hepatic Veno-Occlusive Disease Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction. Sinusoidal Obstruction Syndrome,Veno-Occlusive Disease, Hepatic,Hepatic Veno Occlusive Disease,Disease, Hepatic Veno-Occlusive,Hepatic Veno-Occlusive Diseases,Syndrome, Sinusoidal Obstruction,Veno Occlusive Disease, Hepatic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Allogeneic bone marrow transplantation for severe aplastic anemia.
October 1991, Seminars in hematology,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Severe autoimmune thrombocytopenia after allogeneic bone marrow transplantation for aplastic anemia.
August 2001, International journal of hematology,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation--clinical and immunological considerations.
September 1995, Bone marrow transplantation,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant.
November 1991, Bone marrow transplantation,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Allogeneic bone marrow transplantation for severe aplastic anemia: the Vancouver experience.
April 1995, Clinical and investigative medicine. Medecine clinique et experimentale,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
[Allogeneic bone marrow transplantation for aplastic anemia].
September 1990, Nihon rinsho. Japanese journal of clinical medicine,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Allogeneic bone marrow transplantation for aplastic anemia.
March 2024, International journal of hematology,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation.
August 1997, Bone marrow transplantation,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia.
March 1981, JAMA,
J H Lee, and K H Lee, and S J Choi, and Y J Min, and J G Kim, and S Kim, and J S Lee, and S H Kim, and C J Park, and H S Chi, and W K Kim
Allogeneic bone marrow transplantation for fourteen patients with severe aplastic anemia.
April 1996, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
Copied contents to your clipboard!